JACC: CASE REPORTS © 2020 THE AUTHORS. PUBLISHED BY ELSEVIER ON BEHALF OF THE AMERICAN COLLEGE OF CARDIOLOGY FOUNDATION. THIS IS AN OPEN ACCESS ARTICLE UNDER THE CC BY-NC-ND LICENSE (http://creativecommons.org/licenses/by-nc-nd/4.0/).

MINI-FOCUS ISSUE: TRANSCATHETER INTERVENTIONS

INTERMEDIATE

IMAGING VIGNETTE: CLINICAL VIGNETTE

Deep Sedation in a Patient Undergoing Transfemoral Tricuspid Valve Repair Using the PASCAL System



Miriam X. Arikan, MD, Rezo Jorbenadze, MD, Elli Tavlaki, MD, Jürgen Schreieck, MD, Tobias Geisler, MD

ABSTRACT

A 70-year-old man with severe tricuspid regurgitation and large coaptation gap (0.8 cm) was referred to transfemoral valve repair using the PASCAL system. The procedure was successful in reducing tricuspid regurgitation. The PASCAL device facilitated maximum leaflet insertion and to span large coaptation gap in severe tricuspid regurgitation without ventilation maneuvers under general anesthesia. (Level of Difficulty: Intermediate.) (J Am Coll Cardiol Case Rep 2020;2:1109-11) © 2020 The Authors. Published by Elsevier on behalf of the American College of Cardiology Foundation. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

70-year-old man presented with recurrent cardiac decompensation. In 2017 he already underwent successful edge-to-edge mitral valve repair with the MitraClip system because of severe mitral regurgitation. At that time there was no relevant tricuspid regurgitation (TR). His medical history included a coronary 3-vessel disease with highly impaired left ventricular function and a primary prophylactic implantation of an implantable cardioverter-defibrillator system. Transesophageal echocardiography revealed a remaining low-degree mitral regurgitation and a new secondary severe (torrential) TR along the implantable cardioverter-defibrillator lead with a large coaptation gap of 8 mm (Figure 1A). The right ventricle was enlarged with reduced ventricular function (tricuspid annular plane systolic excursion 16 mm) and a systolic pulmonary artery pressure of 57 mm Hg. Based on the decision of our interdisciplinary heart team, a percutaneous approach for TR repair was chosen. The procedure was performed under deep sedation (DS) with a total duration of 2 h and 46 min and without the presence of an anesthesiologist. Propofol (375 mg) was administered continuously for DS. IV anesthesia was delivered by piritramide (3 mg) before initiation of propofol sedation. The level of sedation was adjusted to DS based on a Richmond Agitation Sedation Scale score of -2 to -3. A nasopharyngeal airway was used. Intraprocedural conversion to general anesthesia (GA) was not required. After clasping the posterior and septal leaflet with the PASCAL device producing a double orifice (Figure 1A) TR could be reduced from very severe to moderate TR (Figures 1B and 1C). The 3-dimensional effective regurgitation orifice area could be reduced from pre-transfemoral tricuspid valve repair 0.49 cm² to 0.28 cm² after clasping. There was no postinterventional functional tricuspid stenosis (Pmean 2 mm Hg at 60 beats/min). Because of prolonged peri-interventional transesophageal echocardiography and known esophageal varicose caused by cirrhosis cardiac, the patient was observed in the intensive care unit for 18 h and could be transferred to intermediate care unit. There was no major bleeding, no major adverse cardiac and cerebrovascular events,

Manuscript received January 27, 2020; revised manuscript received April 29, 2020, accepted May 13, 2020.

From the University of Tuebingen, Medical Clinic, Department of Cardiology and Angiology, Tübingen, Germany. Measures were taken by the researchers to gain patient consent and to protect patient rights according to local EC policies. Dr. Schreieck has received Congress travel support. Dr. Geisler has received a research grant by Edwards outside the submitted work. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.

The authors attest they are in compliance with human studies committees and animal welfare regulations of the authors' institutions and Food and Drug Administration guidelines, including patient consent where appropriate. For more information, visit the *JACC: Case Reports* author instructions page.


ABBREVIATIONS AND ACRONYMS

DS = deep sedation

GA = general anesthesia

TR = tricuspid regurgitation

conversion to surgery, or major vascular complication using DS approach. The patient was discharged from hospital with significantly improved symptoms. The transthoracic echocardiography showed a stable position of the PASCAL device and sustained procedural success with moderate TR after 3-month follow-up. Implantable cardioverter-defibrillator function and lead position was not affected.



(A) Large coaptation gap between the tricuspid valve leaflets before clasping (left) and double orifice after successful clasping of septal and posterior leaflets in transesophageal echocardiography (TEE) imaging (right). (B) Severe tricuspid regurgitation (TR) before clasping (left) and moderate TR after successful clasping (right) in transthoracic echocardiography imaging. (C) TEE image of pre-interventional TR (left) and after successful placement of the PASCAL device (right). (D) Placing the PASCAL device between the posterior and septal leaflet at the site of maximum TR jet close to the implantable cardioverter-defibrillator pacemaker lead (left) and independent clasping of the posterior leaflet first and the septal leaflet second allowing to maximize leaflet insertion and to span the large coaptation gap (right). (E) TEE 3-dimensional view on tricuspid valve.

There are limited data on the use of the PASCAL system for treating severe TR under GA from small series of patients with good short-term results (1,2). We report the first transfemoral implantation of the PASCAL system in a tricuspid valve with severe TR using DS that resulted in a significant TR reduction. The performance of this procedure using DS instead of GA might be beneficial for this group of patients with high operative risk. In particular with tricuspid interventions it is difficult to plan the total amount of device implantations. Therefore a careful planning with adequate pre-procedural imaging is of utmost importance to accurately identify the pathomechanism and geometry of TR. This allows to minimize duration of transcatheter TR interventions under DS.

Larger studies are required to confirm the feasibility, safety, and efficacy of the transfemoral tricuspid valve repair with the PASCAL system using DS in patients with severe TR. The possibility of independent leaflet grasping using the PASCAL device facilitates maximum leaflet insertion and to span large coaptation gaps in severe TR (**Figures 1D and 1E**) without ventilation maneuvers under GA as being important for simultaneous grasping of tricuspid leaflets with the MitraClip (3).

ACKNOWLEDGMENTS Measures were taken by the researchers to gain patient consent and to protect patient rights according to local EC policies. The authors acknowledge support by Open Access Publishing Fund of University of Tübingen.

ADDRESS FOR CORRESPONDENCE: Dr. Miriam X. Arikan, University of Tuebingen, Medical Clinic, Department of Cardiology and Angiology, Otfried-Müller-Straße 10, 72076 Tübingen, Germany. E-mail: miriam. arikan@med.uni-tuebingen.de.

REFERENCES

1. Fam NP, Braun D, von Bardeleben RS, et al. Compassionate use of the PASCAL transcatheter valve repair system for severe tricuspid regurgitation. J Am Coll Cardiol Intv 2019;12:2488-95.

2. Fam NP, Ho EC, Zahrani M, Samargandy S, Connelly KA. Transcatheter tricuspid valve repair

with the PASCAL system. J Am Coll Cardiol Intv 2018;11:407-8.

3. Nickenig G, Kowalski M, Hausleiter J, et al. Transcatheter treatment of severe tricuspid regurgitation with the edge-to-edge MitraClip technique. Circulation 2017;135:1802-14. **KEY WORDS** deep sedation, PASCAL device, tricuspid regurgitation